Skip to main content

Table 5 Sensitivity and secondary analyses with propensity score matching and friction cost model (values per capita in 2008)

From: The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study

  Baseline (GM) PS model Friction cost model
  ATTa(in €) ATTa(in €) % changeb ATTa(in €) % changeb
Sickness fund perspective      
  Direct medical costs 2330 2024 −13.14 2330 0
  Direct non-medical costs 167 161 −3.58 167 0
  Total costs 2496 2184 −12.49 2496 0
Societal perspective      
  Direct medical costs 2366 2059 −12.97 2366 0
  Direct non-medical costs 5875 5790 −1.44 5875 0
  Indirect costs 7487 7573 1.15 359 −95.26
  Total costs 15,728 15,422 −1.95 8599 −44.24
  1. aaverage treatment costs of the treated (ATT) represent excess costs attributable to Marfan.
  2. bpercentage change compared with baseline GM model.